

High diagnostic rate of whole genome sequencing in primary ciliary dyskinesia

Holly A Black^{1,2}, Sophie Marion de Proce^{1*}, Jose L Campos^{3*}, Alison Meynert³, Mihail Halachev³, Joseph A Marsh³, Robert A Hirst⁴, Chris O'Callaghan⁴, Scottish Genomes Partnership, Javier Santoyo-Lopez⁵, Jennie Murray^{2,3}, Kenneth Macleod⁶, Don S Urquhart^{6,7}, Stefan Unger^{6,7}, Timothy J Aitman^{1^}, Pleasantine Mill^{3^}

¹ Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

² South East of Scotland Genetics Service, Western General Hospital, Edinburgh, UK

³ MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

⁴ Centre for PCD Diagnosis and Research, Department of Respiratory Sciences, University of Leicester, UK

⁵ Edinburgh Genomics, Edinburgh, UK

⁶ Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK

⁷ Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

* These authors contributed equally to the manuscript

^ Joint senior authors

Summary: Whole genome sequencing (WGS) yielded a high genetic diagnostic rate (100%) in eight Scottish patients with clinically diagnosed primary ciliary dyskinesia (PCD) by detection of large structural variants, homology modelling and identification of a novel disease gene with a dominant mode of inheritance. Prioritised WGS may facilitate early genetic diagnosis in PCD.

27

28

29 **Abstract**

30 Aim: Primary ciliary dyskinesia (PCD) is a genetic disorder affecting motile cilia. Most cases
31 are inherited recessively, due to variants in more than 50 genes that result in abnormal or
32 absent motile cilia. This leads to chronic upper and lower airway disease, sub-fertility and
33 laterality defects in some cases. Given overlapping clinical features and genetic
34 heterogeneity, diagnosis can be difficult and often occurs late. Of those tested, an estimated
35 30% of genetically screened PCD patients still lack a molecular diagnosis. Here, we aimed to
36 identify how readily a genetic diagnosis could be made in a clinically diagnosed population
37 using whole genome sequencing (WGS) to facilitate identification of pathogenic variants in
38 known genes as well as identify novel PCD candidate genes.

39 Methods: WGS was used to screen for variants causing PCD in 8 clinically diagnosed PCD
40 patients, sequenced as trios where parental samples were available.

41 Results: Seven of the eight cases (87.5%) had homozygous or biallelic variants in *DNAH5*,
42 *DNAAF4* or *DNAH11* that were classified as pathogenic or likely pathogenic. Three of the
43 variants were deletions, ranging from 3kb to 13kb, for which WGS identified precise
44 breakpoints, permitting confirmation by Sanger sequencing. WGS yielded a high genetic
45 diagnostic rate from this clinically diagnosed population, in part through detection of
46 structural variants as well as identification of a *de novo* variant in a novel PCD gene *TUBB4B*.

47 Conclusion: A molecular diagnosis allows for appropriate clinical management for cases and
48 their families, including prediction of phenotypic features correlated to genotype. Here, WGS
49 uplifted genetic diagnosis in cases of clinically diagnosed PCD by identifying structural variants
50 and novel modes of inheritance in new candidate genes. Our study suggests that WGS could
51 be a powerful part of the PCD diagnostic toolkit to increase the current molecular diagnostic
52 yield from 70%. It provides important new insight into our understanding of fundamental
53 biology of motile cilia as well as of variation in the non-coding genome in PCD.

54

55

56 **Introduction**

57 Primary ciliary dyskinesia (PCD, OMIM: PS244400) is a genetic disorder of motile cilia (1–3),
58 highly structurally organised organelles that project from the surface of the cells. Their
59 organised structure allows the cilia to beat in a coordinated manner to effectively propel
60 fluids across the surface of the airways, brain ventricles and reproductive tracts. However, in
61 PCD, these cilia have an abnormal structure or function, resulting in static cilia, cilia that beat
62 in an uncoordinated manner, or a complete absence of cilia (2,3). This can result in a chronic
63 respiratory disease, due to impaired mucociliary clearance, as well as hydrocephaly, laterality
64 defects (e.g. situs inversus) and fertility defects in a subset of patients. PCD often presents at
65 birth as unexplained neonatal respiratory distress. Affected children then present with
66 variable clinical features including a daily wet cough, chronic respiratory tract infections,
67 rhinitis, sinusitis and otitis media. Over time, these can lead to debilitating long-term
68 complications, including bronchiectasis and hearing impairment (1–6).

69

70 However, PCD is a heterogeneous disorder that has significant phenotypic overlap with other
71 genetic respiratory diseases, such as cystic fibrosis and primary immunodeficiency. The
72 current clinical diagnostic work-up for suspected PCD cases requires a battery of highly
73 specialised tests (7,8). This includes detection of low nasal nitric oxide (nNO), as well as high-
74 speed video microscopy (HSVM) to assess cilia beating pattern and frequency and
75 transmission electron microscopy (TEM) to assess the cilia ultrastructure from a nasal brush
76 biopsy. Abnormalities identified in cilia structure and/or beating pattern or in the presence of
77 clinical features such as chronic oto-sinopulmonary symptoms can be used to confirm a
78 diagnosis of PCD (1,2,6,8,9). Access to diagnostic testing is limited to a small number of highly
79 specialised units in the UK. Families must travel for testing, often over long distances and
80 sometimes on multiple occasions. Even in those patients with a clinical diagnosis of PCD, 21%
81 had normal ciliary ultrastructure (10). Therefore, additional sensitive and accessible
82 diagnostic techniques acceptable to patients of all ages are required.

83

84 PCD is a genetically heterogeneous disorder. The majority of cases are autosomal recessively
85 inherited, with over 50 genes currently associated with PCD (1,2,6,11,12). Mutations in these

86 genes account for approximately 70% of PCD cases screened, suggesting additional causal
87 genes exist and/or more complicated structural variants (SVs) are being missed in known
88 genes (13). The genes associated with PCD encode proteins involved in cilia structure, cilia
89 assembly or regulatory complexes. There is often a correlation between the affected gene
90 and the defects in cilia motility or ultrastructure observed at diagnosis (1,6,7,9). However, this
91 is not always the case: it is estimated that 9-20% of PCD cases have normal or inconclusive
92 ultrastructure by TEM (14). Similarly normal or non-diagnostic HSVM results complicate
93 diagnosis for a significant portion of known PCD genes (15). nNO is also considered a useful
94 screening test prior to referral for nasal brushing. While low nNO measurements may be
95 indicative of PCD in patients lacking clear ultrastructural defects, its use, particularly in young
96 children, has not been universally rolled out across PCD centres (16,17) and patients with
97 mutations in at least some PCD genes show normal nNO levels (18,19). In such suspected
98 cases, where a clinical diagnosis is unclear, a genetic diagnosis is an important means to
99 confirm PCD (1,5,6,20). However, genetic testing often occurs late in the diagnostic work-up
100 for PCD (7). Recent guidelines have recommended studies to investigate the utility of genetic
101 testing in the PCD diagnostic pathway, particularly as next generation sequencing (NGS) is
102 increasingly available (8,21,22).

103

104 In this study, we investigated the utility of whole genome sequencing (WGS) to detect
105 disease-causing variants in children and young adults with a clinical diagnosis of PCD. We
106 selected a non-endogamous population where PCD was clinically confirmed to test whether
107 WGS could effectively improve the molecular diagnostic yield of PCD. WGS would provide
108 unbiased genome coverage beyond exons of ~50 genes associated with PCD whilst
109 simultaneously detecting a range of variants, from single nucleotide changes, small indels as
110 well as complicated SVs, which may be missed by targeted sequencing approaches. Eight
111 patients were recruited, alongside parental samples where available. This led to a genetic
112 diagnosis for all eight cases, three of whom had a pathogenic deletion of 3 kb-13 kb and one
113 patient had a de novo missense variant p.P259L in a novel candidate gene *TUBB4B*.

114

115

116 **Materials and Methods**

117 *Patient cohort*

118 Eight patients with a confirmed clinical diagnosis of PCD (50% female), aged 6 to 31 years,
119 were recruited to the study. Signed and informed consent was obtained from the affected
120 individual as well as relatives through approved protocols. Sample IDs were assigned and the
121 key known only those within the research group. Clinical phenotypes are shown in **Table 1**.
122 For details of blood samples, DNA extraction, and analysis of sample ethnicity see
123 Supplementary Methods and **Supplementary Figure 1**. The study was approved by the
124 London-West London and Gene Therapy Advisory Committee Research Ethics Committee
125 (REC number 11/LO/0883).

126

127 *Whole Genome Sequencing*

128 DNA was sequenced by WGS at Edinburgh Genomics. Libraries were prepared using the
129 Illumina TruSeq PCR-free protocol and sequenced on the Illumina HiSeq X platform. The
130 average yield per sample was 136 Gb, with mean coverage of 36x (range 33.9-38.3).

131

132 *Gene Panel, data analysis and variant classification*

133 A virtual gene panel of 146 genes was created, which included the known ‘green’ 34 PCD
134 genes plus 107 suspected ciliopathy genes that may have respiratory features based on the
135 PCD PanelApp panel (v1.14) with five additional genes identified in the literature (*CFAP300*,
136 *DNAH6*, *DNAJB13*, *STK36* and *TTC25*) (23–25). Analysis of variants was carried out as described
137 in Supplementary Methods. Additional analyses were carried out across the *FOXJ1* locus for
138 Case 3, in whom no diagnostic variants were identified using the virtual gene panel. A
139 genome-wide expanded analysis identified a *de novo* missense mutation p.P259L
140 (chr9:g.137242994:C>T (hg38)) in the gene *TUBB4B* only in the patient, and not present in
141 either parent (26).

142

143 *Modelling of whole exome sequencing data*

144 A whole exome sequencing (WES)-like subset of the WGS data was obtained by extracting
145 only the reads mapping to the regions in the TWIST Exome Capture Kit (using samtools v1.6)
146 from the BAM file for each sample. WES CNV calling was performed by ExomeDepth (v1.1.15)
147 as detailed in Supplementary Methods.

148

149 *Homology modelling of DNAH11 and location of missense variants*

150 A homology model of the C-terminal region of the DNAH11 motor domain (residues 3348-
151 4504) was built using PHYRE2 (27,28). The effects of mutations in the C-terminal domain (CTD)
152 (residues 4124-4504) on protein stability were modelled with FoldX (29). Sequences of human
153 dynein genes were aligned with MUSCLE (30) and the sequence alignment was visualised with
154 MView (31). Further details are given in the Supplementary Methods.

155
156

157 **Results**

158 Eight PCD patients were recruited to the study as six trios, one proband-mother duo and one
159 singleton (**Table 1**). All eight cases had a confirmed clinical diagnosis of PCD, following a nasal
160 brush biopsy. In all cases, nasal brushings were undertaken for clinical suspicion of PCD.
161 Presentations and phenotype severity were varied and are summarised in **Table 1**.

162

163 Using a virtual PCD panel approach to initially screen the WGS, we confirmed genetic
164 diagnosis for seven of the eight cases (**Table 2**). Three cases had biallelic pathogenic and/or
165 likely pathogenic variants in the outer dynein arm heavy chain subunit gene *DNAH5*, which
166 has previously been shown to contribute to the largest proportion of PCD cases among
167 populations of European descent (1). Case 1 had a hemizygous nonsense variant (c.5281C>T,
168 p.(Arg1761Ter)), inherited from the mother and previously reported in PCD cases (32,33), and
169 an overlapping 13kb deletion on the other allele, inherited from the father (**Supplementary**
170 **Figure 3**). Case 2 had two nonsense variants in *DNAH5*, c.3949C>T, p.(Gln1317Ter), which was
171 previously reported (34), and the c.5281C>T, p.(Arg1761Ter) variant. ddPCR was used to
172 phase the variants in Case 2 (**Supplementary Figure 4**). Case 4 had a single base pair deletion,
173 resulting in a frameshift and premature termination codon (PTC) (c.10815del,
174 p.(Pro3606Hisfs)), and a single base pair duplication, resulting in direct creation of a PTC
175 (c.13458dup, p.(Asn4487Ter)), which were shown to be in trans through trio-based phasing.
176 Both variants have been reported previously in PCD cases (33). All three cases with biallelic
177 variants in *DNAH5* were shown to have absence or defects of outer dynein arms on TEM
178 (**Figure 1**), with Case 1 and Case 2 also shown to have static cilia (**Table 1, Supplementary**
179 **Video 1**). This is consistent with loss of *DNAH5*, which has been shown to result in outer
180 dynein arm truncation and immotile cilia (33). All three share a similar clinical phenotype,

181 with chronic wet cough, sinus problems and recurrent chest infections. Hearing loss was also
182 noted in cases 2 and 4.

183

184 Two cases had likely pathogenic variants in the cytoplasmic axonemal dynein assembly factor
185 *DNAAF4* (*DYX1C1*), necessary for assembly and/or stability of the inner and outer dynein arms
186 (**Table 2**) (35). Case 5 had a homozygous 3.5kb deletion encompassing exon 7 of *DNAAF4*,
187 which was also heterozygous in the mother. There was no evidence of uniparental disomy
188 and, given Case 5 is also reported to have an affected sibling, it is likely the father also carries
189 the 3.5kb deletion, although the father's DNA was unavailable. This variant has previously
190 been reported in PCD (35). Ultrastructural analysis was consistent with previous reports for
191 *DNAAF4* mutations, with reports of absent dynein arms (35) (**Figure 1**) and immotile cilia
192 shown on HSVM. Case 6 had a maternally-inherited nonsense variant (c.856G>T,
193 p.(Glu286Ter)) and a paternally-inherited 3.1 kb deletion encompassing the last two exons of
194 *DNAAF4*, predicted to disrupt the C-terminal tetratricopeptide-like helical domain region
195 (TPR) by deleting the final 71 amino acids, as well as the 3'UTR. We predict this allele to be
196 loss-of-function as the resulting transcript is predicted to be subject to nonsense-mediated
197 decay. Case 6 has bronchiectasis with a recurrent need for antibiotics. He has no ear or
198 hearing problems and situs solitus.

199

200 A further two cases had pathogenic or likely pathogenic variants in the outer dynein arm
201 heavy chain subunit *DNAH11*. Case 7 had a homozygous missense variant in *DNAH11* (c.13373
202 C>T, p.(Pro4458Leu)) previously reported in PCD cases (36,37), at a low frequency in gnomAD
203 and *in silico* predictions support pathogenicity (**Table 2**). There was sufficient evidence to
204 classify the variant as likely pathogenic using ACMG guidelines (38,39). Case 8 had a
205 heterozygous 2 bp deletion, resulting in a PTC (c.10221_10222del, p.(Cys3409Trpfs)), which
206 was classified as pathogenic (**Table 2**). The second variant was a heterozygous missense
207 (c.13288G>C, p.(Gly4430Arg)). This variant is at a low frequency in gnomAD and *in silico*
208 predictions support pathogenicity, but it has not previously been reported in PCD cases. As
209 the variant is in trans with the c.10221_10222del variant, shown by phasing with parental
210 samples, there is sufficient evidence to classify the variant as likely pathogenic (**Table 2**). Both
211 Case 7 and Case 8 were shown to have a normal cilia ultrastructure with a dysmotile
212 phenotype (**Figure 1, Supplementary Video 2**), consistent with loss of *DNAH11*, which

213 localises to the proximal portion of respiratory cilia (40) . There is however phenotypic
214 variability between Case 7 (situs inversus with dextrocardia and recurrent chest infections)
215 and Case 8 (chronic wet cough and recurrent ear infections, with situs solitus).

216

217 The two missense variants in *DNAH11* both reside at the 3' C-terminal domain (CTD) of the
218 axonemal dynein heavy chain. While there is no structure available for DNAH11, there are
219 homologous structures of other dynein proteins. To investigate the effects of the *DNAH11*
220 missense mutations on protein structure, we built a homology model of the DNAH11 motor
221 domain. Both mutations occur within the CTD, on the outer side of the dynein motor dimer
222 (**Figure 2A**) and are intriguingly very close to each other in three-dimensional space (**Figure**
223 **2B**), separated by only 4.2 Å.

224

225 Molecular modelling of the missense mutations using the program FoldX (29) predicts that
226 the Gly4430Arg should be extremely disruptive to protein structure, with a $\Delta\Delta G$ of 10.9
227 kcal/mol. We also modelled all other CTD missense variants presented in the gnomAD v2.1
228 database (41) . Remarkably, out of 269 variants (**Supplementary Table 1**), Gly4430Arg has the
229 highest $\Delta\Delta G$ and therefore is predicted to be the most damaging. Moreover, this position is
230 fully conserved across all human dyneins (**Figure 2C**). This strongly suggests that Gly4430Arg
231 is pathogenic due to its disruptive effects on protein structure.

232

233 In contrast to Gly4430Arg, Pro4458Leu is predicted to be relatively mild at a structural level,
234 with a $\Delta\Delta G$ of 1.1 kcal/mol, making it only the 65th most damaging out of 269 variants
235 (**Supplementary Table 1**). However, this residue is highly conserved, existing as a proline
236 across all human dyneins except DNAH1, where it is an alanine. Thus, while Pro4458 is unlikely
237 to cause a severe destabilisation of protein structure, its remarkable proximity to Gly4430
238 combined with a moderate structural perturbation and high conservation are supportive of
239 pathogenicity.

240

241 To assess whether the three deletion variants identified in Cases 1, 5 and 6 would have been
242 identified using WES, as opposed to WGS, the WGS data was subsetted to create a WES-like
243 dataset for each sample (**Supplementary Figure 2**). CNV calling using ExomeDepth was able
244 to identify the *DNAH5* variant c.5272-955_6197del p.(?) in both the proband and father for

245 Family 1. However, the deletion, which spans five exons and has a breakpoint within exon 37,
246 was called as covering only 4 of the 5 affected exons in the proband. The single exon deletion
247 of *DNAAF4* c.784-1037_894-2012del p.(?) was identified for the proband in Family 5, where
248 it is homozygous, but not in the heterozygous mother. The *DNAAF4* deletion c.1048-
249 149_*1048del p.(?) identified in Family 6 was not detected in the proband or father, despite
250 both carrying the variant.

251

252 The phenotype of Case 3 is particularly relevant as ultrastructural analysis revealed ciliary
253 agenesis (**Supplementary Video 3**), sometimes referred to as reduced generation of multiple
254 motile cilia (RGMC), a specific subtype of PCD. In addition, Case 3 has shunted hydrocephalus,
255 having undergone initial ventriculo-peritoneal (VP) shunt insertion neonatally, and a
256 subsequent VP shunt revision as an adolescent. To date, few genes have been implicated in
257 this RGMC phenotype by recessive inheritance, *CCNO* (cyclin O) and *MCIDAS* (multicilin)
258 (42,43) but no pathogenic or potentially pathogenic variants were identified in either gene.
259 Heterozygous de novo mutations in the master motile ciliogenesis transcriptional regulator
260 *FOXJ1* were identified as the first autosomal dominant cause of a distinct PCD-like condition,
261 associated with chronic respiratory disease, laterality defects and hydrocephalus (18). Similar
262 cellular defects are observed with reduced apical docking of centrioles and fewer cilia, but a
263 focused analysis revealed no identifiable pathogenic mutations in the *FOXJ1* locus. An
264 expanded, whole genome analysis for SNP and indel candidates produced a very limited list
265 of variants (**Supplementary Table 2**). This included a de novo missense mutation p.P259L
266 (chr9:g.137242994:C>T (hg38)) in the gene *TUBB4B* only in the patient, and not present in
267 either parent or found on gnomAD 4.0 or other publicly available databases. Whilst
268 interpretation of pathogenicity from a single patient is limiting, as part of a large international
269 collaboration, we were able to identify a further eleven patients with PCD carrying *TUBB4B*
270 variants identified by next-generation sequencing (NGS) (26). This included five patients with
271 PCD-only carrying the identical p.P259L (chr9:g.137242994:C>T) variant, one carrying a
272 different missense p.P259S (chr9:g.137242993:C>T (hg38)) variant and one patient carried an
273 in-frame ten amino acid duplication p.F242_R251dup (chr9: g.137242941_137242970dup
274 (hg38)) (26). Moreover, we also identified a recurrent de novo *TUBB4B* variant four patients
275 with a p.P358S (chr9:g.137243290:C>T (hg38)) variant, who presented with features of both
276 PCD with Leber congenital amaurosis and sensorineural hearing loss. In-depth functional

277 analyses in cell and animal models confirmed pathogenicity and distinct dominant-negative
278 mechanisms of action to cause different disease presentations (26). In summary, our WGS
279 strategy was very effective at identifying a novel PCD disease gene with the first report of
280 dominant negative disease mechanisms.

281

282

283

284 **Discussion**

285 In this study, WGS of affected probands and family members led to a genetic diagnosis in all
286 eight PCD patients, representing 11 different mutations in 3 autosomal recessive PCD genes
287 and 1 de novo mutation in a novel autosomal dominant PCD candidate *TUBB4B*. In Case 3, a
288 patient with features of reduced generation of motile cilia and hydrocephalus, no pathogenic
289 variants would be identified in a panel-based approach, even with targeted sequencing of
290 potential candidates for known RGMC loci. The diagnostic rate of 100% in our small study is
291 higher than previous reports, in which 60-70% of cases received a genetic diagnosis based on
292 the known PCD gene panels (1,5,12,13,20), 75% on extended NGS panels (44) and 68-94% by
293 WES (45–48).

294

295 Next-generation sequencing (NGS) technologies continue to revolutionise rare genetics
296 research and clinical diagnostics, where the advantages of WES versus WGS are often fiercely
297 debated. Cheaper in terms of costs of sequencing, analysis and data storage, WES is generally
298 preferred as a front-line diagnostic tool. WES, however, has several issues in terms of
299 evenness of genome coverage and sequence bias, particular for copy number variations
300 (CNV). In comparison, several studies have found more accurate variant calls as well as even
301 and unbiased coverage of coding regions are generated by WGS (49,50). Our analysis was
302 focused on known and candidate PCD genes, screening simultaneously for single nucleotide
303 variants (SNVs), small indels and more complex SVs. In three cases, pathogenic deletions were
304 identified, ranging in size from 3kb to 13kb. Modelling of our WGS data to represent WES-like
305 data suggested that WES data would only have identified the deletion in one of these three
306 cases, in which the deletion was homozygous. Since our WES-like model has more uniform
307 coverage than true WES data, our WES-like model could be considered more reliable for CNV

308 calling than real-life WES sequence. However, we acknowledge that our model is based on
309 36X WGS data, whereas WES would be nearer 100X in practice but coverage does vary across
310 commercial platforms. The ability to detect SVs in PCD is of importance and consistent with
311 recent diagnostic guidelines for PCD, which highlighted that causal SVs and intronic mutations
312 can be missed due to the large number and size of PCD genes (8,21). Further, WES would not
313 have provided the precise breakpoint information that allowed confirmation of the three
314 deletion variants by Sanger sequencing.

315

316 Where WGS was clearly advantageous was PCD disease gene discovery in patients without
317 biallelic variants in known genes or in the one recent example of autosomal dominant
318 inheritance (*FOXJ1*) or in the few cases of X-linked recessive inheritance (*RPGR*, *PIH1D3*,
319 *OFD1*) (12). In Case 3, WES would have likely identified the de novo SNV in *TUBB4B*, as WES
320 panels identified SNVs in the other 11 *TUBB4B* patients (26). Here, the clear advantage of
321 WGS was to rule out potential non-coding alterations in the known RGMC PCD genes of
322 known inheritance such as *FOXJ1* modes as to quickly prioritise novel candidates in our first
323 proband. As such, a clear benefit of WGS, similar to WES, is that its findings are future-proof;
324 the data generated can be re-screened for PCD-causing variants identified subsequent to
325 genetic testing, if initial testing is inconclusive. However, only WGS will allow future analysis
326 of non-coding genome for variations in regulatory elements such as of transcription factor
327 binding sites that may underlie a subset of unsolved PCD cases.

328

329 Whatever the modality, increased genetic testing for PCD is critical. Currently genetic testing
330 for PCD sits as an additional step to confirm diagnosis by both European and American
331 guidelines (8,21,22). As shown here, and elsewhere, genetic testing can accurately diagnose
332 PCD where standard clinical procedures are unavailable, impractical or inconclusive (45–
333 47,51) Importantly, a delayed PCD diagnosis is associated with worse prognosis (52,53). A
334 clinical diagnosis of PCD requires specialised, invasive testing, and frequently necessitates
335 travel over considerable distances to specialist centres. These tests are unsuitable for critically
336 ill neonates and for those unable to travel or unwilling to undergo invasive testing. Genetic
337 testing for PCD may therefore have utility in the neonatal period or in infancy that may have
338 been preferred to the diagnostic odyssey of the patients in this study, where the age of
339 diagnosis was between 5 and 12 years. Suggested clinical criteria for genetic testing in PCD

340 could include term babies who become unwell at >12 hours of age with respiratory disease,
341 lobar collapse, situs inversus and/or an unexpectedly high or prolonged oxygen requirement
342 (54,55). Increasing availability, reducing costs and recognised clinical utility of NGS platforms
343 such as WGS in the neonatal and paediatric intensive care unit setting would be consistent
344 with such indications (50,51,54,56–59). Moreover, either WES or WGS would help rule out
345 other confounding clinical presentations such as primary immune deficiency disorders (PIDs),
346 with overlapping symptoms of frequent, often severe, airway infections as well as recurrent
347 otitis media, and sinusitis (60–62). Both platforms are advantageous as they allow analysis of
348 all potential causative genes, known and novel, thus faster to keep up with recently reported
349 genes that may not yet be included on PCD-gene panels. Indeed such technologies may prove
350 to be more cost- and time-effective as providing a molecular diagnosis test for PCD than
351 conventional clinical gene panels (45,46,48,63). A prospective study would appear to be
352 warranted, to define the optimum criteria for genetic testing and diagnostic yield in neonates
353 and older infants and children with respiratory symptomatology to help expedite PCD
354 diagnosis.

355

356 While earlier genetic testing for PCD is clearly a priority, PCD also remains underdiagnosed.
357 PCD has an estimated incidence of 1 in 7,500 births, rising to 1 in 2,300 in endogamous
358 populations (64,65). In North America, it is estimated that only 1,000 patients have a
359 confirmed diagnosis of PCD as opposed to the predicted ~25,000- 50,000 these rates would
360 suggest to be affected with PCD (66). Similar underdiagnosis is reported in the UK, where
361 these prevalence estimates suggest there should be at least 8,900 people with PCD in the UK;
362 less than a quarter of these are known to the NHS highly specialised PCD service (67). A large
363 portion of these missing patients are likely adult patients within primary care or
364 bronchiectasis clinics, as suggested by one study which found 12% of bronchiectasis patients
365 had pathogenic variants in known motile ciliopathy genes (68). Increased genetic testing as a
366 first-pass diagnostic test in these suspected cases of PCD could be a way of controlling access
367 to more labour-intensive clinical and pathological diagnostic work-up in limited specialist
368 centres.

369

370 PCD needs to enter the precision medicine era. A genetic diagnosis is key to improved patient
371 prognosis as we better understand genotype-phenotype relations (69) and critically to being

372 trial-ready as much-needed genetic therapies come online (70,71). Increased genetic testing
373 is also being combined with a curated worldwide database, similar to that of CFTR2 for Cystic
374 Fibrosis (72), to enable a better understanding of these genotype-phenotype relations in PCD
375 called CiliaVar (73). Such a database will significantly facilitate interpretation of variants, of
376 which 21% has been suggested to be variants of unknown significance (VUS) (73). For
377 example, in Cases 7 and 8 in our study, structural modelling of the CTD of *DNAH11* aided the
378 assignment of pathogenicity of two missense variants, with one predicted to be detrimental
379 to protein stability and the second, in close proximity to the first, shown to be highly
380 conserved.

381

382 In conclusion, this study demonstrates the benefits of using WGS to obtain a genetic diagnosis
383 for PCD, through its ability to detect SNVs and SVs simultaneously as well as detecting variants
384 in genes outwith current gene panels. The detection of multi-kilobase deletions in three of
385 the seven diagnosed cases highlights the need to detect SVs as part of the genetic testing for
386 PCD. It also allowed rapid prioritisation of SNVs in novel candidate genes with dominant
387 modes of inheritance. Practically and financially, WGS would likely sit behind current standard
388 of care panel-based or WES diagnostic platforms. Given the high genetic diagnostic rate
389 observed here and elsewhere (44,45,47,48), we suggest that genetic testing should be an
390 early step in the current diagnostic pathway for PCD, particularly in cases where nasal brush
391 biopsy is unavailable. By moving clinical and genetic diagnostic pathways in PCD earlier,
392 ideally to early life, we could have a transformative long-term reduction in morbidity with
393 access to specialist care and disease-modifying therapies commenced before permanent lung
394 damage.

395

396

397 **Acknowledgements**

398 We thank the PCD families who participated in this study and the UK PCD Family Support
399 Group for support; Dr Lee Murphy and colleagues at the Wellcome Trust Clinical Research
400 Facility; Edinburgh Genomics for sequencing and analysis; and the Brompton Hospital PCD
401 Diagnostic Service and South East Scotland Genetics Service for clinical support.

402

403 **Support statement:** The Scottish Genomes Partnership is funded by the Chief Scientist Office
404 of the Scottish Government Health Directorates [SGP_1] and the MRC Whole Genome
405 Sequencing for Health and Wealth Initiative (MC_PC_15080). We acknowledge support from
406 the MRC (PM: MC_UU_00007_14, MR_Y015002_1); an MRC Career Development Award
407 (MR_M02122X_1) and Lister Prize Fellowship to JAM; an NHS Research Scotland fellowship
408 to SU; and an NRS/R+D fellowship from the NHS Lothian R&D office to DU.

409

410 **Competing interests:** We confirm that no competing interests.

411

412

413

414

415

416

413 **Figures:**

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437





Figure 1: Ultrastructure analysis supports genetic diagnosis for outer arm dynein variants in PCD.

(left) *DNAH5* variants disrupt outer dynein arms (red arrowhead = disrupted, black arrowheads normal) across axonemes of nasal brush samples from cases HG-001, HG-002 and HG-004. (right) In contrast, *DNAH11* variants do not uniformly disrupt outer dynein arms (black arrowheads) in cilia from nasal brush of case HG-007. Disruption of both inner and outer dynein arms (red arrowheads) is observed in *DNAAF4* variants, as shown for HG-005. Scale bars = 100 nm.

438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458



459 **Figure 2: Structural and evolutionary analysis of DNAH11 missense mutations.** (A) Structure of the
460 human cytoplasmic dynein-1 dimer (PDB ID: 5NUG), with the location of the C-terminal domain
461 coloured beige, and the equivalent sites of the DNAH11 mutations highlighted in red. (B) Homology
462 model of the DNAH11 C-terminal domain with the sites of the missense mutations shown in red,
463 along with the $\Delta\Delta G$ values calculated with FoldX. (C) Multiple sequence alignment of human dynein
proteins around the region where the missense mutations occur.

480 **Table 1: Clinical details of PCD cases.**

Case number	Samples recruited	Sex	Ethnicity	Age at diagnosis	Age at recruitment	Ciliary ultrastructure	Cilia motility	nNO (ppb)	Current FEV1 (% predicted)	NRD	Chronic wet cough	Regular IV antibiotics	Recurrent infections	Rhinosinusitis	Bronchiectasis	Recurrent ear infection	Hearing loss	Situs inversus	Dextrocardia
1	Trio	F	EUR	11-15	16-20	Absent outer dynein arms	Static cilia	<5	83	U	Y	N	Y	Y	N	Y	N	N	N
2	Proband only	M	EUR	6-10	11-15	Outer dynein arm defect	Static cilia	8.5	90	Y	Y	Y	N	Y	Y	Y	Y	N	N
3	Trio	F	EUR	11-15	11-15	Ciliary agenesis	N/A	15.5	47	Y	Y	Y	Y	Y	Y	N	Y	N	N
4	Trio	M	EUR	0-5	6-10	Outer dynein arm defect	Static cilia	75	82	Y	Y	N	Y	Y	N	N	Y	N	N
5	Proband and Mother	F	EUR	11-15	31-35	Complete absence of dynein arm	Static cilia	U	U	N	Y	U	Y	Y	Y	Y	N	N	N
6	Trio	M	EUR	U	21-25	Unknown	Unknown	8.5	62	U	Y	Y	Y	Y	Y	N	N	N	N
7	Trio	M	SAS	6-10	6-10	Normal	Dysmotile	49.5	87	N	N	N	Y	Y	U	N	N	Y	Y
8	Trio	F	EUR	6-10	11-15	Normal	Dysmotile	22	75	U	Y	N	Y	Y	N	Y	N	N	N

481 Y= yes; N= no; U= unknown; F= female; M= male; NRD= neonatal respiratory distress; nNO= nasal nitric oxide; ppb= parts per billion; FEV1=
482 forced expiratory volume in one second; IV= intravenous; EUR= European; SAS= South Asian

483

468 **Table 2: Genetic variants identified in PCD cases.** Variants were classified according to the ACMG/ACGS guidelines (38,39); the criteria met for each variant
 469 are shown.

Case number	Gene	Transcript	dbSNP ID	Variant(s)	Zygoty	gnomAD allele frequency (v4.0.0)	In silico predictions	ACMG/ACGS Classification	ClinVar Accession Number
1	<i>DNAH5</i>	NM_001369.3	N/A	c.5272-955_6197del p.(?)	Compound heterozygous	Absent ^a	N/A	P (PVS1, PM3, PP4)	SCV001334255
			rs148891849	c.5281C>T, p.(Arg1761Ter) (32-34)		6x10 ⁻⁵	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334256
2	<i>DNAH5</i>	NM_001369.3	rs1769508571	c.3949C>T, p.(Gln1317Ter)(74)	Compound heterozygous	1.6x10 ⁻⁶	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334257
			rs148891849	c.5281C>T, p.(Arg1761Ter)(32-34)		6x10 ⁻⁵	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334256
3	<i>TUBB4B</i>	NM_006088.6	N/A	c.776C>T, p.(Pro259Leu) (26)	Heterozygous	Absent	Grantham Score 98 AlphaMissense 0.998 (LP)	P (PS2, PM2, PP2, PP3)	SCV002770069.1
4	<i>DNAH5</i>	NM_001369.3	rs397515540	c.10815del, p.(Pro3606Hisfs) (33)	Compound heterozygous	4.1x10 ⁻⁴	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334258
			rs775696136	c.13458dup, p.(Asn4487Ter) (33)		1.6x10 ⁻⁴	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334259

5	<i>DNAAF4</i>	NM_130810.4	N/A	c.784-1037_894-2012del p.(?) (35)	Homozygous	2.5x10 ⁻⁴ ^b	N/A	P (PVS1, PM3_str, PP4)	SCV001334260
6	<i>DNAAF4</i>	NM_130810.4	rs770136467	c.856G>T, p.(Glu286Ter)	Compound heterozygous	2.6x10 ⁻⁵	N/A	P (PVS1, PM2, PP4)	SCV001334261
			N/A	c.1048-149_*1048del p.(?)		Absent ^a	N/A	P (PVS1, PM3, PP4)	SCV001334262
7	<i>DNAH11</i>	NM_001277115.2	rs72658835	c.13373C>T, p.(Pro4458Leu) (36,37,47,51)	Homozygous	8.4x10 ⁻⁵	Grantham Score 98 REVEL 0.377 (Uncertain) AlphaMissense 0.625 (LP)	LP (PM2, PM3, PP3, PP4)	SCV001334263
8	<i>DNAH11</i>	NM_001277115.2	rs1450540788	c.10221_10222del, p.(Cys3409Trpfs)	Compound heterozygous	1.5x10 ⁻⁵	N/A	P (PVS1, PM2, PP4)	SCV001334264
			N/A	c.13288G>C, p.(Gly4430Arg) (75)		2x10 ⁻⁶	Grantham score 125 REVEL 0.641 (Damaging) AlphaMissense 0.813 (LP)	LP (PM1_sup, PM2, PM3_str, PP3, PP4)	SCV001334265

P= pathogenic; LP= likely pathogenic; N/A= not applicable. ^aabsent from gnomAD SV and gnomAD CNV. ^bfrequency from gnomAD SV.

470
471
472

473

474 **REFERENCES**

- 475 1. Lucas JS, Davis SD, Omran H, Shoemark A. Primary ciliary dyskinesia in the genomics age.
476 *Lancet Respir Med.* 2020 Feb;8(2):202–16.
- 477 2. Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary
478 Dyskinesia (PCD): A genetic disorder of motile cilia. *Transl Sci Rare Dis.* 2019 Jul 4;4(1–2):51–
479 75.
- 480 3. Wallmeier J, Nielsen KG, Kuehni CE, Lucas JS, Leigh MW, Zariwala MA, et al. Motile
481 ciliopathies. *Nat Rev Dis Primers.* 2020 Sep 17;6(1):77.
- 482 4. Damseh N, Quercia N, Rumman N, Dell SD, Kim RH. Primary ciliary dyskinesia: mechanisms
483 and management. *Appl Clin Genet.* 2017 Sep 19;10:67–74.
- 484 5. Mirra V, Werner C, Santamaria F. Primary ciliary dyskinesia: an update on clinical aspects,
485 genetics, diagnosis, and future treatment strategies. *Front Pediatr.* 2017 Jun 9;5:135.
- 486 6. Dunsky K, Menezes M, Ferkol TW. Advances in the diagnosis and treatment of primary ciliary
487 dyskinesia: A review. *JAMA Otolaryngol Head Neck Surg.* 2021 Jun 17;
- 488 7. Halbeisen FS, Shoemark A, Barbato A, Boon M, Carr S, Crowley S, et al. Time trends in
489 diagnostic testing for primary ciliary dyskinesia in Europe. *Eur Respir J.* 2019 Oct 24;54(4).
- 490 8. Shoemark A, Dell S, Shapiro A, Lucas JS. ERS and ATS diagnostic guidelines for primary ciliary
491 dyskinesia: similarities and differences in approach to diagnosis. *Eur Respir J.* 2019 Sep
492 5;54(3).
- 493 9. Raidt J, Wallmeier J, Hjejij R, Onnebrink JG, Pennekamp P, Loges NT, et al. Ciliary beat pattern
494 and frequency in genetic variants of primary ciliary dyskinesia. *Eur Respir J.* 2014
495 Dec;44(6):1579–88.
- 496 10. Jackson CL, Behan L, Collins SA, Goggin PM, Adam EC, Coles JL, et al. Accuracy of diagnostic
497 testing in primary ciliary dyskinesia. *Eur Respir J.* 2016 Mar;47(3):837–48.
- 498 11. Horani A, Ferkol TW. Advances in the genetics of primary ciliary dyskinesia: clinical
499 implications. *Chest.* 2018 Sep;154(3):645–52.
- 500 12. Legendre M, Zaragosi L-E, Mitchison HM. Motile cilia and airway disease. *Semin Cell Dev Biol.*
501 2021 Feb;110:19–33.
- 502 13. Knowles MR, Zariwala M, Leigh M. Primary Ciliary Dyskinesia. *Clin Chest Med.* 2016
503 Sep;37(3):449–61.
- 504 14. Goutaki M, Pedersen ESL. Phenotype-genotype associations in primary ciliary dyskinesia:
505 where do we stand? *Eur Respir J.* 2021 Aug 5;58(2).
- 506 15. Shapiro AJ, Ferkol TW, Manion M, Leigh MW, Davis SD, Knowles MR. High-Speed
507 Videomicroscopy Analysis Presents Limitations in Diagnosis of Primary Ciliary Dyskinesia. *Am J*
508 *Respir Crit Care Med.* 2020 Jan 1;201(1):122–3.
- 509 16. Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia.
510 *Eur Respir J.* 2012 Oct;40(4):1024–32.

- 511 17. Shapiro AJ, Josephson M, Rosenfeld M, Yilmaz O, Davis SD, Polineni D, et al. Accuracy of Nasal
512 Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic
513 Review and Meta-analysis. *Ann Am Thorac Soc*. 2017 Jul;14(7):1184–96.
- 514 18. Wallmeier J, Frank D, Shoemark A, Nöthe-Menchen T, Cindric S, Olbrich H, et al. De Novo
515 Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of
516 Left/Right Body Asymmetry. *Am J Hum Genet*. 2019 Nov 7;105(5):1030–9.
- 517 19. Raidt J, Krenz H, Tebbe J, Große-Onnebrink J, Olbrich H, Loges NT, et al. Limitations of Nasal
518 Nitric Oxide Measurement for Diagnosis of Primary Ciliary Dyskinesia with Normal
519 Ultrastructure. *Ann Am Thorac Soc*. 2022 Aug;19(8):1275–84.
- 520 20. Kurkowiak M, Ziętkiewicz E, Witt M. Recent advances in primary ciliary dyskinesia genetics. *J*
521 *Med Genet*. 2015 Jan;52(1):1–9.
- 522 21. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, et al. European Respiratory
523 Society guidelines for the diagnosis of primary ciliary dyskinesia. *Eur Respir J*. 2017 Jan 4;49(1).
- 524 22. Shapiro AJ, Davis SD, Polineni D, Manion M, Rosenfeld M, Dell SD, et al. Diagnosis of primary
525 ciliary dyskinesia. an official american thoracic society clinical practice guideline. *Am J Respir*
526 *Crit Care Med*. 2018 Jun 15;197(12):e24–39.
- 527 23. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp
528 crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet*.
529 2019 Nov;51(11):1560–5.
- 530 24. Primary ciliary disorders (Version 1.40) [Internet]. [cited 2024 Feb 17]. Available from:
531 <https://panelapp.genomicsengland.co.uk/panels/178/>.
- 532 25. Home - OMIM - NCBI [Internet]. [cited 2024 Feb 17]. Available from:
533 <https://www.ncbi.nlm.nih.gov/omim>
- 534 26. Mechaussier S, Dodd DO, Yeyati PL, McPhie F, Attard T, Shoemark A, et al. *TUBB4B* variants
535 specifically impact ciliary function, causing a ciliopathic spectrum. *medRxiv*. 2022 Oct 21;20.
- 536 27. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein
537 modeling, prediction and analysis. *Nat Protoc*. 2015 Jun;10(6):845–58.
- 538 28. Zhang K, Foster HE, Rondelet A, Lacey SE, Bahi-Buisson N, Bird AW, et al. Cryo-EM Reveals
539 How Human Cytoplasmic Dynein Is Auto-inhibited and Activated. *Cell*. 2017 Jun
540 15;169(7):1303-1314.e18.
- 541 29. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein
542 complexes: a study of more than 1000 mutations. *J Mol Biol*. 2002 Jul 5;320(2):369–87.
- 543 30. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
544 *Nucleic Acids Res*. 2004 Mar 19;32(5):1792–7.
- 545 31. Brown NP, Leroy C, Sander C. MView: a web-compatible database search or multiple
546 alignment viewer. *Bioinformatics*. 1998;14(4):380–1.
- 547 32. Faily M, Bartoloni L, Letourneau A, Munoz A, Falconnet E, Rossier C, et al. Mutations in
548 DNAH5 account for only 15% of a non-preselected cohort of patients with primary ciliary
549 dyskinesia. *J Med Genet*. 2009 Apr;46(4):281–6.

- 550 33. Hornef N, Olbrich H, Horvath J, Zariwala MA, Fliegau M, Loges NT, et al. DNAH5 mutations are
551 a common cause of primary ciliary dyskinesia with outer dynein arm defects. *Am J Respir Crit*
552 *Care Med.* 2006 Jul 15;174(2):120–6.
- 553 34. Hagen EM, Sicko RJ, Kay DM, Rigler SL, Dimopoulos A, Ahmad S, et al. Copy-number variant
554 analysis of classic heterotaxy highlights the importance of body patterning pathways. *Hum*
555 *Genet.* 2016 Dec;135(12):1355–64.
- 556 35. Tarkar A, Loges NT, Slagle CE, Francis R, Dougherty GW, Tamayo JV, et al. DDX11 is required
557 for axonemal dynein assembly and ciliary motility. *Nat Genet.* 2013 Sep;45(9):995–1003.
- 558 36. Knowles MR, Leigh MW, Carson JL, Davis SD, Dell SD, Ferkol TW, et al. Mutations of DNAH11
559 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. *Thorax.* 2012
560 May;67(5):433–41.
- 561 37. Guan W-J, Li J-C, Liu F, Zhou J, Liu Y-P, Ling C, et al. Next-generation sequencing for identifying
562 genetic mutations in adults with bronchiectasis. *J Thorac Dis.* 2018 May;10(5):2618–30.
- 563 38. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the
564 interpretation of sequence variants: a joint consensus recommendation of the American
565 College of Medical Genetics and Genomics and the Association for Molecular Pathology.
566 *Genet Med.* 2015 May;17(5):405–24.
- 567 39. Ellard S. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020
568 [Internet]. 2020 [cited 2024 Feb 17]. Available from:
569 [https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-](https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf)
570 [01-2020.pdf](https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf)
- 571 40. Dougherty GW, Loges NT, Klinkenbusch JA, Olbrich H, Pennekamp P, Menchen T, et al.
572 DNAH11 localization in the proximal region of respiratory cilia defines distinct outer dynein
573 arm complexes. *Am J Respir Cell Mol Biol.* 2016 Aug;55(2):213–24.
- 574 41. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational
575 constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020 May
576 27;581(7809):434–43.
- 577 42. Boon M, Wallmeier J, Ma L, Loges NT, Jaspers M, Olbrich H, et al. MCIDAS mutations result in
578 a mucociliary clearance disorder with reduced generation of multiple motile cilia. *Nat*
579 *Commun.* 2014 Jul 22;5:4418.
- 580 43. Wallmeier J, Al-Mutairi DA, Chen C-T, Loges NT, Pennekamp P, Menchen T, et al. Mutations in
581 CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple
582 motile cilia. *Nat Genet.* 2014 Jun;46(6):646–51.
- 583 44. Fassad MR, Patel MP, Shoemark A, Cullup T, Hayward J, Dixon M, et al. Clinical utility of NGS
584 diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort. *J Med*
585 *Genet.* 2020 May;57(5):322–30.
- 586 45. Gileles-Hillel A, Mor-Shaked H, Shoseyov D, Reiter J, Tsabari R, Hevroni A, et al. Whole-exome
587 sequencing accuracy in the diagnosis of primary ciliary dyskinesia. *ERJ Open Research.* 2020
588 Oct;6(4).
- 589 46. Shamseldin HE, Al Mogarri I, Alqwaiee MM, Alharbi AS, Baqais K, AlSaadi M, et al. An exome-

- 590 first approach to aid in the diagnosis of primary ciliary dyskinesia. *Hum Genet.* 2020
591 Oct;139(10):1273–83.
- 592 47. Wheway G, Thomas NS, Carroll M, Coles J, Doherty R, Genomics England Research
593 Consortium, et al. Whole genome sequencing in the diagnosis of primary ciliary dyskinesia.
594 *BMC Med Genomics.* 2021 Sep 23;14(1):234.
- 595 48. Marshall CR, Scherer SW, Zariwala MA, Lau L, Paton TA, Stockley T, et al. Whole-Exome
596 Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia. *G3 (Bethesda).*
597 2015 Jul 2;5(8):1775–81.
- 598 49. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing
599 is more powerful than whole-exome sequencing for detecting exome variants. *Proc Natl Acad
600 Sci USA.* 2015 Apr 28;112(17):5473–8.
- 601 50. Kingsmore SF, Cakici JA, Clark MM, Gaughran M, Feddock M, Batalov S, et al. A randomized,
602 controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome
603 and exome sequencing in ill infants. *Am J Hum Genet.* 2019 Oct 3;105(4):719–33.
- 604 51. Hao C, Guo R, Liu J, Hu X, Guo J, Yao Y, et al. Exome sequencing as the first-tier test for
605 pediatric respiratory diseases: A single-center study. *Hum Mutat.* 2021 Jul;42(7):891–900.
- 606 52. Halbeisen FS, Pedersen ESL, Goutaki M, Spycher BD, Amirav I, Boon M, et al. Lung function
607 from school age to adulthood in primary ciliary dyskinesia. *Eur Respir J.* 2022 Oct 20;60(4).
- 608 53. Kuehni CE, Frischer T, Strippoli MPF, Maurer E, Bush A, Nielsen KG, et al. Factors influencing
609 age at diagnosis of primary ciliary dyskinesia in European children. *Eur Respir J.* 2010
610 Dec;36(6):1248–58.
- 611 54. Nogee LM, Ryan RM. Genetic testing for neonatal respiratory disease. *Children (Basel).* 2021
612 Mar 11;8(3).
- 613 55. Machogu E, Gaston B. Respiratory Distress in the Newborn with Primary Ciliary Dyskinesia.
614 *Children (Basel).* 2021 Feb 18;8(2).
- 615 56. French CE, Delon I, Dolling H, Sanchis-Juan A, Shamardina O, Mégy K, et al. Whole genome
616 sequencing reveals that genetic conditions are frequent in intensively ill children. *Intensive
617 Care Med.* 2019 May;45(5):627–36.
- 618 57. NICUSeq Study Group, Krantz ID, Medne L, Weatherly JM, Wild KT, Biswas S, et al. Effect of
619 Whole-Genome Sequencing on the Clinical Management of Acutely Ill Infants With Suspected
620 Genetic Disease: A Randomized Clinical Trial. *JAMA Pediatr.* 2021 Dec 1;175(12):1218–26.
- 621 58. Farnaes L, Hildreth A, Sweeney NM, Clark MM, Chowdhury S, Nahas S, et al. Rapid whole-
622 genome sequencing decreases infant morbidity and cost of hospitalization. *NPJ Genom Med.*
623 2018 Apr 4;3:10.
- 624 59. Petrikin JE, Cakici JA, Clark MM, Willig LK, Sweeney NM, Farrow EG, et al. The NSIGHT1-
625 randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic
626 diagnosis in critically ill infants. *NPJ Genom Med.* 2018 Feb 9;3:6.
- 627 60. Khalturina EO, Degtyareva ND, Bairashevskaja AV, Mulenkova AV, Degtyareva AV. Modern
628 diagnostic capabilities of neonatal screening for primary immunodeficiencies in newborns.
629 *Clin Exp Pediatr.* 2021 Oct;64(10):504–10.

- 630 61. Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of
631 IUIS phenotypical classification for human inborn errors of immunity. *J Clin Immunol*. 2022 Oct
632 6;42(7):1508–20.
- 633 62. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of
634 multimodal single-cell data. *Cell*. 2021 Jun 24;184(13):3573-3587.
- 635 63. Platt CD, Zaman F, Bainter W, Stafstrom K, Almutairi A, Reigle M, et al. Efficacy and economics
636 of targeted panel versus whole-exome sequencing in 878 patients with suspected primary
637 immunodeficiency. *J Allergy Clin Immunol*. 2021 Feb;147(2):723–6.
- 638 64. O’Callaghan C, Chetcuti P, Moya E. High prevalence of primary ciliary dyskinesia in a British
639 Asian population. *Arch Dis Child*. 2010 Jan;95(1):51–2.
- 640 65. Hannah WB, Seifert BA, Truty R, Zariwala MA, Ameel K, Zhao Y, et al. The global prevalence
641 and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database
642 analysis. *Lancet Respir Med*. 2022 May;10(5):459–68.
- 643 66. O’Connor MG, Mosquera R, Metjian H, Marmor M. CHEST Reviews: Primary Ciliary Dyskinesia.
644 CHEST Pulmonary. 2023;
- 645 67. NHS England Highly Specialised Services 2020/21 [Internet]. [cited 2024 Feb 17]. Available
646 from: [https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN00328-highly-](https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN00328-highly-specialised-services-2020-2021.pdf)
647 [specialised-services-2020-2021.pdf](https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN00328-highly-specialised-services-2020-2021.pdf)
- 648 68. Shoemark A, Griffin H, Wheway G, Hogg C, Lucas JS, Genomics England Research Consortium,
649 et al. Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in
650 bronchiectasis. *Eur Respir J*. 2022 Nov 17;60(5).
- 651 69. Shoemark A, Rubbo B, Legendre M, Fassad MR, Haarman EG, Best S, et al. Topological data
652 analysis reveals genotype-phenotype relationships in primary ciliary dyskinesia. *Eur Respir J*.
653 2021 Aug 5;58(2).
- 654 70. Raidt J, Maitre B, Pennekamp P, Altenburg J, Anagnostopoulou P, Armengot M, et al. The
655 disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. *ERJ Open*
656 *Research*. 2022 Jul;8(3).
- 657 71. ReCode doses first subject in Phase I primary ciliary dyskinesia trial [Internet]. [cited 2024 Feb
658 17]. Available from: [https://www.clinicaltrialsarena.com/news/recode-primary-ciliary-](https://www.clinicaltrialsarena.com/news/recode-primary-ciliary-dyskinesia-trial/)
659 [dyskinesia-trial/](https://www.clinicaltrialsarena.com/news/recode-primary-ciliary-dyskinesia-trial/)
- 660 72. Welcome to CFTR2 | CFTR2 [Internet]. [cited 2024 Feb 17]. Available from: <https://cftr2.org/>
- 661 73. Mani R, Gomes M, González AR, Hogg C, Morris-Rosendahl D, Maitre B, et al. Development
662 and first results of the BEAT-PCD international Primary Ciliary Dyskinesia gene variant
663 database: CiliaVar. *Paediatric respiratory epidemiology*. European Respiratory Society; 2021.
664 p. PA3458.
- 665 74. Aprea I, Nöthe-Menchen T, Dougherty GW, Raidt J, Loges NT, Kaiser T, et al. Motility of
666 efferent duct cilia aids passage of sperm cells through the male reproductive system. *Mol*
667 *Hum Reprod*. 2021 Feb 27;27(3).
- 668 75. Leung GKC, Mak CCY, Fung JLF, Wong WHS, Tsang MHY, Yu MHC, et al. Identifying the genetic
669 causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome

670 sequencing (WES). BMC Med Genomics. 2018 Oct 25;11(1):93.

High diagnostic rate of whole genome sequencing in primary ciliary dyskinesia

Supplementary Material and Methods

Holly A Black^{1,2}, Sophie Marion de Proce^{1*}, Jose L Campos^{3*}, Alison Meynert³, Mihail Halachev³, Joseph A Marsh³, Robert A Hirst⁴, Chris O'Callaghan⁴, Scottish Genomes Partnership, Javier Santoyo-Lopez⁵, Jennie Murray^{2,3}, Kenneth Macleod⁶, Don S Urquhart^{6,7}, Stefan Unger^{6,7}, Timothy J Aitman^{1^}, Pleasantine Mill^{3^}

¹ Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

² South East of Scotland Genetics Service, Western General Hospital, Edinburgh, UK

³ MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

⁴ Centre for PCD Diagnosis and Research, Department of Respiratory Sciences, University of Leicester, UK

⁵ Edinburgh Genomics, Edinburgh, UK

⁶ Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK

⁷ Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

* These authors contributed equally to the manuscript

^ Joint senior authors

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Ranked list of most disruptive reported variants ($\Delta\Delta G$) in the C-terminal domain (CTD) of DNAH11 as predicted by FoldX. $\Delta\Delta G$ represents the change in free energy by mutation/design of proteins as predicted by the FoldX algorithm, where $\Delta\Delta G = \Delta G_{\text{fold}}(\text{mutation}) - \Delta G_{\text{fold}}(\text{wild type})$.

Supplementary Table 2: Genome wide list of variants detected in patient HG-003 by Slivar.

Supplementary File 1: Gene panel used for variant filtering with G2P under a biallelic inheritance model


Supplementary File 2: Gene panel used for variant filtering with G2P under a monoallelic inheritance model

Supplementary File 3 Droplet digital PCR for variant phasing.


Supplementary Video 1: HSVM for cases 1, 2 and 4, which have a genetic diagnosis in *DNAH5*, showing static cilia

Supplementary Video 2: HSVM for cases 7 and 8, which have a genetic diagnosis in *DNAH11*, showing dysmotile cilia


Supplementary Video 3: HSVM for case 3, showing ciliary agenesis



Supplementary Figure 1: Principal component analysis (PCA) of study samples compared to 1000 Genomes project samples. Peddy was used to predict ancestry of the samples used in the study by comparison with the 1000 Genomes samples. The 1000 Genomes samples (dots) are colour-coded by location. The samples in our study are represented by squares. All samples were predicted to be of European ancestry (purple squares), except three (orange squares), which were predicted to have South Asian ancestry. AFR= African; AMR= American; EAS= East Asian; EUR= European; SAS= South Asian.




Supplementary Figure 2: Alignments of the modelled WES data showing sufficient coverage to call the deletion variants identified in Cases 1, 5 and 6. A: Alignment for Family 1, showing coverage of exons 32-38 of *DNAH5*. B: Alignment for Family 5, showing coverage of exons 6 to 8 of *DNAAF4*. C: Alignment for Family 6, showing coverage exons 8-10 of *DNAAF4*.




Supplementary Figure 3: Sanger sequencing confirms 13kb deletion in *DNAH5* in Case 1. Alignments of the WGS data for Family 1 show a drop in read depth to approximately 50% of that of the surrounding regions across a 13kb region of *DNAH5* in the proband and the father. This spans from intron 32 to exon 37. PCR and Sanger sequencing across the breakpoints confirms this deletion. * indicates the position of the c.5281C>T nonsense variant, which is on the maternal haplotype and is therefore hemizygous in the proband.


c.3949C and c.5281C




c.3949T and c.5281C



c.3949C and c.5281T



c.3949T and c.5281T



Supplementary Figure 4: Drop phase results confirms the two *DNAH5* nonsense variants are on different haplotypes for Case 2. The c.3949 variant was assayed using FAM probes and the c.5281 variant was assayed using HEX probes. For each combination of alleles, a representative result from genomic DNA (left) and *PacI*-digested DNA (right) is shown. Each figure plots the number of FAM-only positive (blue), HEX-only positive (green), FAM and HEX-positive (orange) and negative (grey) droplets. The linkage % is shown for each test. (Details see Supplementary File 3).

SUPPLEMENTARY METHODS

Patient cohort

Eight young people with PCD (50% female), aged 6 to 31 years (mean=15, SD= 7.9), were recruited to the study within the Department of Paediatric Respiratory and Sleep Medicine at the Royal Hospital for Sick Children, Edinburgh, and the South East Scotland Genetics service. All eight cases had a confirmed clinical diagnosis of PCD, following TEM and/or HSVM of a nasal brush biopsy sample. The screening and diagnostic testing was performed according to the PCD National Service protocols, with investigations including nNO, nasal brush biopsies analysed by HSVM for ciliary beat frequency and pattern and quantitative electron microscopy for ciliary ultrastructure. Clinical phenotypes are shown in **Table 1**. Blood samples were collected in EDTA tubes from the patients and parents, where available. DNA was extracted using the Chemagic DNA blood kit (Chemagen) or the Nucleon Bacc3 kit (GE Healthcare). Sample ethnicity was assessed using Peddy (v4.0.6) (1) (**Supplementary Figure 1**).

Gene Panel, sequence data analysis and variant classification

BCBio-Nextgen (0.9.7) was used for alignment and variant detection. This used bwa mem (0.7.13) to align reads to the hg38/GRCh38 reference genome (2), samblaster (0.1.22) to mark duplicate fragments (3) and GATK (3.4-0-g7e26428) for indel realignment and base recalibration (4). GATK HaplotypeCaller was used to calculate genotype likelihoods. Joint genotyping and quality control, including kinship estimates to confirm sample relatedness, were performed using in-house pipelines with GATK (4.0.2.1) following the GATK best practices. Variants were annotated using Ensembl variant effect predictor (VEP 90) (5).

A bespoke gene panel of 146 genes was created (**Supplementary Files 1 and 2**), based on the PCD PanelApp panel (v1.14) and five additional genes identified in the literature (*CFAP300*, *DNAH6*, *DNAJB13*, *STK36* and *TTC25*) (6–8). Variants (SNPs and small indels) were filtered to retain only those within genes on the gene panel and then further filtered to identify candidate variants by inheritance model (both biallelic and monoallelic), transcript consequence, and population allele frequency using the G2P plugin for VEP (9). Variants were assessed using Alamut (v2.13) (10) and classified using the ACMG variant

interpretation guidelines (11,12). Any variants classified as pathogenic or likely pathogenic were validated using Sanger sequencing and were submitted to ClinVar. Parental samples were used to determine the phase of compound heterozygous variants, except for Case 2, which used droplet digital PCR (ddPCR) for phasing (**Supplementary File 3**).

SVs were called using Manta (13) and Canvas (version 1.38) (14). The detection of SVs can be challenging and it is common practise to use complementary approaches to detect them (15). Manta detects SVs using discordant paired-end and split reads, whereas Canvas relies on changes in read coverage. We searched for any SVs present in our gene panel that were inherited from either parent. We also searched for de novo SVs for cases where both parents were available. SVs were confirmed *in silico* using SV-Plaudit (16), a tool for rapidly curating SV predictions, and/or using the Integrative Genomics Viewer tool (17). Candidate variants were confirmed in the laboratory by PCR and Sanger sequencing across the deletion breakpoints.

For Case 3, we did not find any diagnostic variants using our gene panel. As *FOXJ1* was only recently identified as a PCD gene and hence was not present on the panel, we searched for SNVs, indels and SVs in Case 3 in this gene, given the ciliary agenesis phenotype observed in this case is associated with *FOXJ1*. We also expanded our analysis for this case to a genome wide search for SNV and small indel candidates with Slivar (0.1.10), following the protocol for rare diseases (<https://github.com/brentp/slivar/wiki/rare-disease> Date accessed: January 2020). A small number of variants was detected (**Supplementary Table 2**) and none were identified that fitted the current modes of inheritance for PCD.

Modelling of whole exome sequencing data

A whole exome sequencing (WES)-like subset of the WGS data was obtained by extracting only the reads mapping to the regions in the TWIST Exome Capture Kit (using samtools v1.6) from the BAM file for each sample. The capture region fully covers the exons affected by copy number variants (CNVs) identified based on the WGS data (**Supplementary Figure 2**). The WES CNV calling was performed using ExomeDepth (v 1.1.15) separately on each individual from the three families in which a pathogenic CNV was identified (Families 1, 5

and 6). As controls, we used WES-like subset data from the WGS data for the other samples in this project (total of 21), from which we excluded any members of the family currently being evaluated. As the WGS data was aligned to GRCh38, we generated a custom reference dataset (exons.GRCh38) required by ExomeDepth, to replace the dataset currently distributed with the ExomeDepth package (exons.hg19); exons.GRCh38 is based on the latest CCDS release (r 22) available for the GRCh38 human genome reference (Available at: www.ncbi.nlm.nih.gov/projects/CCDS/CcidsBrowse.cgi?REQUEST=SHOW_STATISTICS).

Homology modelling of DNAH11 and location of missense variants

A homology model of the C-terminal region of the DNAH11 motor domain (residues 3348-4504) was built using PHYRE2 (18), based upon the cryo-electron microscopy structure of human cytoplasmic dynein-1 (PDB ID: 5NUG) (19). The effects of the mutations in the C-terminal domain (CTD) (residues 4124-4504) on protein stability were modelled with FoldX (20), using default parameters and calculated over 10 replicates. Sequences of human dynein genes were aligned with MUSCLE (21) and the sequence alignment was visualised with MView (22).

SUPPLEMENTARY REFERENCES

1. Pedersen BS, Quinlan AR. Who's Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with Peddy. *Am J Hum Genet.* 2017 Mar 2;100(3):406–13.
2. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009 Jul 15;25(14):1754–60.
3. Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics.* 2014 Sep 1;30(17):2503–5.
4. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010 Sep;20(9):1297–303.
5. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. *Genome Biol.* 2016 Jun 6;17(1):122.
6. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet.* 2019 Nov;51(11):1560–5.
7. Home - OMIM - NCBI [Internet]. [cited 2024 Feb 17]. Available from: <https://www.ncbi.nlm.nih.gov/omim>
8. Primary ciliary disorders (Version 1.40) [Internet]. [cited 2024 Feb 17]. Available from: <https://panelapp.genomicsengland.co.uk/panels/178/>
9. Thormann A, Halachev M, McLaren W, Moore DJ, Svinti V, Campbell A, et al. Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP. *Nat Commun.* 2019 May 30;10(1):2373.
10. Alamut™ Visual Plus - Variant Annotation and Analysis Software [Internet]. [cited 2024 Feb 18]. Available from: <https://www.sophiagenetics.com/platform/alamut-visual-plus/>
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015 May;17(5):405–24.
12. Ellard S. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020 [Internet]. 2020 [cited 2024 Feb 17]. Available from: <https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf>
13. Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics.* 2016 Apr 15;32(8):1220–2.
14. Ivakhno S, Roller E, Colombo C, Tedder P, Cox AJ. Canvas SPW: calling de novo copy number variants in pedigrees. *Bioinformatics.* 2018 Feb 1;34(3):516–8.
15. Cameron DL, Di Stefano L, Papenfuss AT. Comprehensive evaluation and characterisation of short read general-purpose structural variant calling software. *Nat Commun.* 2019 Jul

- 19;10(1):3240.
16. Belyeu JR, Nicholas TJ, Pedersen BS, Sasani TA, Havrilla JM, Kravitz SN, et al. SV-plaudit: A cloud-based framework for manually curating thousands of structural variants. *Gigascience*. 2018 Jul 1;7(7).
 17. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol*. 2011 Jan;29(1):24–6.
 18. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc*. 2015 Jun;10(6):845–58.
 19. Zhang K, Foster HE, Rondelet A, Lacey SE, Bahi-Buisson N, Bird AW, et al. Cryo-EM Reveals How Human Cytoplasmic Dynein Is Auto-inhibited and Activated. *Cell*. 2017 Jun 15;169(7):1303-1314.e18.
 20. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. *J Mol Biol*. 2002 Jul 5;320(2):369–87.
 21. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*. 2004 Mar 19;32(5):1792–7.
 22. Brown NP, Leroy C, Sander C. MView: a web-compatible database search or multiple alignment viewer. *Bioinformatics*. 1998;14(4):380–1.